Table 1. Patient characteristics.

	Total	AITL	PTCL, NOS	NK/TCL	ALK+ALCL	ALK-ALCL	Others
Overall	650	91	65	280	55	33	126
Sex
Male	455 (70.0%)	57 (62.6%)	49 (75.4%)	205 (73.2%)	41 (74.5%)	24 (72.7%)	82 (65.1%)
Female	195 (30.0 %)	34 (37.4%)	16 (24.6%)	75 (26.8%)	14 (25.5%)	9 (27.3%)	44 (34.9%)
Age (yr)
< 60	502 (77.2%)	44 (48.4%)	49 (75.4%)	242 (86.4%)	52 (94.5%)	17 (51.5%)	98 (77.8%)
≥ 60	148 (22.8%)	47 (51.6%)	16 (24.6%)	38 (13.6%)	3 (5.5%)	16 (48.5%)	28 (22.2%)
Stage
I-II	245 (37.7%)	1 (1.1%)	10 (15.4%)	163 (58.2%)	18 (32.7%)	20 (60.6%)	33 (26.2%)
III-IV	405 (62.3%)	90 (98.9%)	55 (84.6%)	117 (41.8%)	37 (67.3%)	13 (39.4%)	93 (73.8%)
LDH*
< ULN	402 (61.8%)	38 (41.8%)	36 (55.4%)	194 (69.3%)	32 (58.2%)	22 (66.7%)	80 (63.5%)
≥ ULN	248 (38.2%)	53 (58.2%)	29 (44.6%)	86 (30.7%)	23 (41.8%)	11 (33.3%)	46 (36.5%)
Extranodal sites
< 2	437 (67.2%)	73 (80.2%)	45 (69.2%)	161 (57.5%)	41 (74.5%)	26 (78.8%)	91 (72.2%)
≥ 2	213 (32.8%)	18 (19.8%)	20 (30.8%)	119 (42.5%)	14 (25.5%)	7 (21.2%)	35 (27.8%)
ECOG
< 2	584 (89.8%)	74 (81.3%)	59 (90.8%)	257 (91.8%)	49 (89.1%)	32 (97/0%)	113 (89.7%)
≥ 2	66 (10.2%)	17 (18.7%)	6 (9.2%)	23 (8.2%)	6 (10.9%)	1 (3.0%)	13 (10.3%)
Risk groups
Low	303 (46.6%)	19 (20.9%)	21 (32.3%)	154 (55%)	31 (56.4%)	19 (57.6%)	59 (46.8%)
Low-intermediate	192 (29.5%)	28 (30.8%)	23 (35.4%)	76 (27.1%)	16 (29.1%)	7 (21.2%)	42 (33.3%)
High-intermediate	111 (17.1%)	29 (31.9%)	17 (26.2%)	37 (13.2%)	5 (9.1%)	5 (15.2%)	18 (14.3%)
High	44 (6.8%)	15 (16.5%)	4 (6.2%)	13 (4.6%)	3 (5.5%)	2 (6.1%)	7 (5.6%)

AITL: angioimmunoblastic T-cell lymphoma; ALK: anaplastic lymphoma kinase positive; ALCL: anaplastic large cell lymphoma; PTCL: peripheral T-cell lymphoma; NKTCL: NK/T cell lymphoma. PTCL, NOS: peripheral T-cell lymphoma, unspecified. LDH: lactate dehydrogenase; ULN: upper limit of normal; ECOG: Eastern Cooperative Oncology Group.

*The upper limit of normal for LDH was defined as 240 IU/L.